thalidomide has been researched along with Thrombocythemia, Essential in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Thrombocythemia, Essential: A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ranimustine was therefore administered starting in July 2011 to control the blood cell count, but the rash associated with Sweet's syndrome persisted." | 1.40 | Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide. ( Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamada, M | 1 |
| Kuroda, H | 1 |
| Yoshida, M | 1 |
| Jomen, W | 1 |
| Abe, T | 1 |
| Sakurai, T | 1 |
| Fujii, S | 1 |
| Maeda, M | 1 |
| Fujita, M | 1 |
| Nagashima, K | 1 |
| Matsuno, T | 1 |
| Sato, M | 1 |
| Kato, J | 1 |
| Yoshimoto, G | 1 |
| Miyamoto, T | 1 |
1 review available for thalidomide and Thrombocythemia, Essential
| Article | Year |
|---|---|
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, | 2014 |
1 other study available for thalidomide and Thrombocythemia, Essential
| Article | Year |
|---|---|
Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide.
Topics: Aged; Blood Cell Count; Bone Marrow; Drug Therapy, Combination; Humans; Lenalidomide; Male; Myelodys | 2014 |